drugset / Trial / NCT01345630
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-08
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Emtricitabine/tenofovir | Unknown | — | — |
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Background | Darunavir | Small molecule | 800 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |
Indications
No indication recorded.